SCHEMBL1128366

SCHEMBL1128366

CSc1ccc(O)cc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
ALOX15 P16050 2/20 0.42
CHRM1 P11229 1/20 0.42
MAOA P21397 1/20 0.42
TBXA2R P21731 1/20 0.42
ADRA1A P35348 1/20 0.42
HTR2B P41595 1/20 0.42
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
ESR2 Q92731 7/20 0.42
ESR1 P03372 6/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ACHE P22303 2/20 0.40
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490395 1.00 CYP3A4 (0.42) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL1928567 0.83 ESR2 (0.48) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL5748285 0.81 ACHE (0.45) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL2481401 0.80 HSD17B10 (0.36) CYP3A4ALOX15ESR2ESR1HSD17B10
SCHEMBL9006588 0.78 TYR (0.41) CYP3A4ALOX15ESR2ESR1HSD17B10
SCHEMBL11092955 0.76 NR1H2 (0.52) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL11731334 0.76 CYP3A4 (0.41) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL11066678 0.76 ESR2 (0.38) CYP3A4ALOX15CHRM1MAOATBXA2R
SCHEMBL735441 0.75 HSD17B10 (0.44) CYP3A4ALOX15TAS1R3TAS1R1HSD17B10
SCHEMBL31417935 0.74 ALOX15 (0.35) CYP3A4ALOX15ESR2ESR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717035-A1 HYBRID COMMUNICATION SYSTEM AND COMMUNICATION METHOD Shenzhen TCL New Technology Co., Ltd (CN) 2026-04-01 EP claimed
EP-3280150-B1 TRANSMISSION METHOD, RECEPTION METHOD, TRANSMISSION DEVICE AND RECEPTION DEVICE PANASONIC IP CORP AMERICA (US) 2026-01-21 EP claimed
WO-2024239247-A1 HYBRID COMMUNICATION SYSTEM AND COMMUNICATION METHOD SHENZHEN TCL NEW TECHNOLOGY CO., LTD. (CN) 2024-11-28 WO claimed
EP-3840313-B1 METHOD AND APPARATUS FOR PACKET TRANSMISSION SUPPORTING DOWNLOADING AND STREAMING SAMSUNG ELECTRONICS CO LTD (KR) 2024-11-27 EP claimed
US-12106747-B2 Receiver, signaling device, and method for receiving emergency information time information SHARP KABUSHIKI KAISHA (JP) 2024-10-01 US claimed
CN-113475087-B Transmitting and receiving method and transmitting and receiving device 海信视像科技股份有限公司 2024-05-31 CN claimed
CN-117837151-A Streaming media data transmission method and device and terminal equipment 深圳TCL新技术有限公司 2024-04-05 CN claimed
EP-3610651-B1 METHOD AND APPARATUS FOR PROVIDING BROADCAST SERVICE SAMSUNG ELECTRONICS CO LTD (KR) 2024-03-13 EP claimed
EP-3217606-B1 TRANSMISSION DEVICE, TRANSMISSION METHOD, RECEPTION DEVICE, AND RECEPTION METHOD SONY GROUP CORP (JP) 2023-11-29 EP claimed
EP-4284007-A2 TRANSMISSION DEVICE, TRANSMISSION METHOD, RECEPTION DEVICE, AND RECEPTION METHOD Sony Group Corporation (JP) 2023-11-29 EP claimed
US-6451830-B1 Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. 2002-09-17 US claimed
US-6448295-B1 TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN G.D. SEARLE & CO. 2002-09-10 US claimed
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2002-08-29 US claimed
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. (US) 2001-08-30 US claimed
EP-1115695-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115694-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity CETP, DBI, MTTP CYP3A4 2162/4885ALOX15 1545/4885CHRM1 3159/4885
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity CETP, PCTP, DBI CYP3A4 3355/4885ALOX15 1770/4885CHRM1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.